Who
Richard E. Uihlein
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Galectin Therapeutics.
In numbers
- Trades disclosed
- 64
- Buys
- 9
- Sells
- 0
- Bought
- $40.8M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 14 Dec 2017
- Last trade
- 31 Jul 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 4 Aug 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $95.5M31,825,235 at $3.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $10.3M2,550,932 at $4.05 | filing |
| 31 Jul 2026filed 4 Aug 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | — | filing |
| 31 Jul 2026filed 4 Aug 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | — | filing |
| 31 Jul 2026filed 4 Aug 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | — | filing |
| 31 Jul 2026filed 4 Aug 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | — | filing |
| 31 Jul 2026filed 4 Aug 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $95.5M31,825,235 at $3.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $10.3M2,550,932 at $4.05 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code A | $40K13,158 at $3.04 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code A | $40K13,158 at $3.04 | filing |
| 23 Jan 2025filed 27 Jan 2025 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 23 Jan 2025filed 27 Jan 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code A | $40K32,520 at $1.23 | filing |
| 24 Jan 2024filed 7 Feb 2024 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 24 Jan 2024filed 7 Feb 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code A | $40K23,256 at $1.72 | filing |
| 26 Sep 2023filed 27 Sep 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,466,204 at $0.00 | filing |
| 26 Sep 2023filed 27 Sep 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —170,000 at $0.00 | filing |
| 26 Sep 2023filed 27 Sep 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —200,000 at $0.00 | filing |
| 26 Sep 2023filed 27 Sep 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —200,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.